billS3686Event Thursday, January 15, 2026Analyzed

Hemp Planting Predictability Act

Neutral

Summary

S3686 (Hemp Planting Predictability Act) is an early-stage bill that would delay stricter hemp product federal controls by two years to November 2028. The bill carries no funding, faces a long legislative path, and has seen zero action since referral on January 15, 2026. Near-term market impact on $TLRY and $SNDL is minimal — both stocks have declined 8-10% in the past week on unrelated sector weakness.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.S3686 is dormant — no action since January 2026 referral; 0% chance of passing before November 2026 deadline.
  • 2.Bill carries $0 funding; economic impact is purely regulatory — maintains current hemp product rules for 2 more years.
  • 3.$TLRY at $6.18 and $SNDL at $1.36 show no catalyst from this bill; both down ~9% in the past week on sector weakness.
  • 4.Long-term structural uncertainty for hemp-derived cannabinoids remains — the 2028 deadline is only delayed, not removed.
  • 5.Only 2 cosponsors on a Senate bill from a mid-tier committee member; insufficient momentum for passage.

Market Implications

($6.18) and $SNDL ($1.36) have already priced in the status quo. This bill changes nothing for the next 6 months. The real risk is the November 2026 deadline — if S3686 fails, stricter federal controls on hemp products take effect, which would negatively impact the revenue streams of both companies. Investors should watch committee action, not the stock price, for signals. The 7-day selloff of 8-10% in both names is unrelated to this legislation and reflects broader cannabis sector weakness.

Full Analysis

  1. On January 15, 2026, Senator Klobuchar (D-MN) introduced S3686 with two cosponsors (Paul, R-KY; Merkley, D-OR). The bill was referred to the Senate Agriculture Committee and has had zero subsequent actions. It remains an early-stage bill with no committee markup, no House companion, and no hearings. The bill would amend the FY2026 agriculture appropriations act (P.L. 119-37) to extend the effective date of stricter hemp product regulations from November 12, 2026 to November 12, 2028.

  2. The money trail: There is zero funding attached. S3686 is a policy delay mechanism — it does not authorize or appropriate any money. The underlying P.L. 119-37 (passed November 2025) reimposed federal controls on certain hemp products effective November 2026; this bill simply pushes that effective date out by 2 years. Economic impact is purely regulatory: maintaining the current looser regime for hemp-derived cannabinoids (CBD, delta-8, etc.) for an additional 24 months.

  3. Structural winners and losers: and $SNDL are the primary publicly traded pure-plays exposed to the US hemp-derived cannabinoid market. Both generate meaningful revenue from CBD and minor cannabinoid products that would face new federal restrictions under the 2026 rules. A delay maintains their current market access. However, neither company has shown a positive near-term revenue catalyst from this bill — the status quo was already expected and priced in. The long regulatory shadow remains since the bill does not repeal the 2026 restrictions, only pushes them back.

  4. Real market data analysis: closed at $6.18 on April 30, 2026, down 8.44% over 7 days and 4.48% over 30 days. The stock is well below its 52-week high of $23.20 and near its 52-week low of $3.50. $SNDL closed at $1.36, down 9.93% over 7 days but up 3.03% over 30 days. Both stocks experienced sharp drops in the final week of April (TLRY from $6.89 to $6.18; SNDL from $1.51 to $1.36). These moves appear driven by broader cannabis sector weakness, not this bill — the bill has been dormant for 3+ months.

  5. Timeline: The bill must clear the Senate Agriculture Committee, pass the full Senate, pass the House, and be signed by the President. With only 2 cosponsors and zero committee actions in 3 months, the path is long and uncertain. The underlying rule changes take effect November 12, 2026 — only 6 months from now. The bill has effectively no chance of passage before that date given its current status. The structural uncertainty for the hemp-derived cannabinoid market persists.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$SNDL● Neutral

What the bill does

Delays by 2 years (to November 2028) the reimposition of federal controls on certain hemp-derived products under P.L. 119-37, maintaining current regulatory status quo.

Who must act

SNDL Inc. — specifically its hemp-derived cannabinoid product distribution and retail operations through its Valens and other subsidiaries.

What happens

No new federal enforcement or market access restrictions on SNDL's hemp-derived products for an additional 2 years, preserving current revenue streams from these products that would otherwise contract under stricter federal controls.

Stock impact

SNDL's hemp/cannabinoid operations (including its Nova Cannabis retail network and Valens extraction services) would face disruption under the 2026 rules. The delay extends the status quo but does not resolve the long-term regulatory overhang on the sector.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

proclamationJun 2, 2026

Further Adjusting the Tariff Regimes for Imports of Aluminum, Steel, and Copper into the United States

This proclamation modifies existing Section 232 tariffs on aluminum, steel, and copper imports by expanding the list of derivative products eligible for a reduced 15% duty to include agricultural equipment and residential HVAC systems, temporarily reducing tariffs on mobile industrial equipment, adding aluminum lithographic plates and steel racks to the derivative tariff coverage, and lowering the threshold for products to qualify as made 'entirely' from American metals from 95% to 85%.